These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 15519888

  • 1. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
    Seckl JR, Walker BR.
    Trends Endocrinol Metab; 2004 Nov; 15(9):418-24. PubMed ID: 15519888
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M, Seckl JR.
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
    Alberti L, Girola A, Gilardini L, Conti A, Cattaldo S, Micheletto G, Invitti C.
    Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR.
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
    Morton NM.
    Mol Cell Endocrinol; 2010 Mar 25; 316(2):154-64. PubMed ID: 19804814
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M, Mikhailidis DP.
    Metabolism; 2013 Jan 25; 62(1):21-33. PubMed ID: 22652056
    [Abstract] [Full Text] [Related]

  • 13. Upregulation of adipose 11-beta-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen.
    Paulsen SK, Nielsen MP, Richelsen B, Bruun JM, Flyvbjerg A, Pedersen SB.
    Obesity (Silver Spring); 2008 Apr 25; 16(4):731-5. PubMed ID: 18379559
    [Abstract] [Full Text] [Related]

  • 14. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM, Seckl JR.
    Front Horm Res; 2008 Apr 25; 36():146-164. PubMed ID: 18230901
    [Abstract] [Full Text] [Related]

  • 15. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
    Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A.
    Am J Physiol Endocrinol Metab; 2005 May 25; 288(5):E957-64. PubMed ID: 15613680
    [Abstract] [Full Text] [Related]

  • 16. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
    Véniant MM, Hale C, Komorowski R, Chen MM, St Jean DJ, Fotsch C, Wang M.
    Diabetes Obes Metab; 2009 Feb 25; 11(2):109-17. PubMed ID: 18479468
    [Abstract] [Full Text] [Related]

  • 17. Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response.
    Chapman KE, Coutinho A, Gray M, Gilmour JS, Savill JS, Seckl JR.
    Ann N Y Acad Sci; 2006 Nov 25; 1088():265-73. PubMed ID: 17192572
    [Abstract] [Full Text] [Related]

  • 18. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
    Walker BR, Andrew R.
    Ann N Y Acad Sci; 2006 Nov 25; 1083():165-84. PubMed ID: 17148739
    [Abstract] [Full Text] [Related]

  • 19. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Pereira CD, Azevedo I, Monteiro R, Martins MJ.
    Diabetes Obes Metab; 2012 Oct 25; 14(10):869-81. PubMed ID: 22321826
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.